抑制剂-话题@MedSci

#抑制剂#

1990篇内容 | 3120人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1852831, encodeId=c735185283101, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=JCEM：钠-葡萄糖协同转运蛋白2抑制剂对左心室功能的有益作用, objectType=article, longId=221645, objectId=82d222164590, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=82d222164590, replyNumber=0, likeNumber=67, createdTime=2022-07-18, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=82d222164590, moduleTitle=JCEM：钠-葡萄糖协同转运蛋白2抑制剂对左心室功能的有益作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=82d222164590)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852858, encodeId=c4a8185285889, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Clin Cancer Res：mTOR抑制剂sapanisertib联合氟维司群治疗芳香化酶抑制剂进展后ER+/ HER2-的绝经后女性晚期乳腺癌患者的疗效, objectType=article, longId=293538, objectId=db002935384a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=db002935384a, replyNumber=0, likeNumber=58, createdTime=2022-11-30, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=db002935384a, moduleTitle=Clin Cancer Res：mTOR抑制剂sapanisertib联合氟维司群治疗芳香化酶抑制剂进展后ER+/ HER2-的绝经后女性晚期乳腺癌患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=db002935384a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1853019, encodeId=eb3a1853019e6, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=J Allergy Clin Immunol：脱氧核糖核酸2抑制剂对银屑病的分子和临床作用, objectType=article, longId=732187, objectId=ea2ae32187b5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ea2ae32187b5, replyNumber=0, likeNumber=82, createdTime=2022-10-22, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ea2ae32187b5, moduleTitle=J Allergy Clin Immunol：脱氧核糖核酸2抑制剂对银屑病的分子和临床作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ea2ae32187b5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852816, encodeId=1eb71852816c5, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Front Oncol：回顾性分析实体恶性肿瘤伴有脑转移患者从免疫检查点抑制剂治疗的获益情况, objectType=article, longId=220855, objectId=b2bf220855c8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b2bf220855c8, replyNumber=0, likeNumber=73, createdTime=2022-10-28, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b2bf220855c8, moduleTitle=Front Oncol：回顾性分析实体恶性肿瘤伴有脑转移患者从免疫检查点抑制剂治疗的获益情况, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b2bf220855c8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852786, encodeId=524a1852e869e, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=JAK抑制剂联合疗法FMX114治疗轻中度特应性皮炎，临床试验中招募了第一位患者, objectType=article, longId=218973, objectId=dbd52189e3d5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dbd52189e3d5, replyNumber=0, likeNumber=73, createdTime=2022-08-30, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dbd52189e3d5, moduleTitle=JAK抑制剂联合疗法FMX114治疗轻中度特应性皮炎，临床试验中招募了第一位患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dbd52189e3d5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852942, encodeId=32df185294267, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Rhizen Pharmaceuticals AG在AACR 2022公布其差异化的PARP和DHODH抑制剂项目的数据, objectType=article, longId=724127, objectId=b5ebe2412785, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b5ebe2412785, replyNumber=0, likeNumber=94, createdTime=2022-11-05, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b5ebe2412785, moduleTitle=Rhizen Pharmaceuticals AG在AACR 2022公布其差异化的PARP和DHODH抑制剂项目的数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b5ebe2412785)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1853048, encodeId=16d31853048c9, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=氯喹/羟氯喹：严重 COVID-19 中的炎症小体抑制剂？, objectType=article, longId=738350, objectId=6658e3835045, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6658e3835045, replyNumber=0, likeNumber=79, createdTime=2023-08-01, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6658e3835045, moduleTitle=氯喹/羟氯喹：严重 COVID-19 中的炎症小体抑制剂？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6658e3835045)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852938, encodeId=212b185293866, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=AACR 2022：第四代EGFR抑制剂BLU-945治疗晚期耐药的NSCLC早期结果公布, objectType=article, longId=724026, objectId=c4f1e2402624, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c4f1e2402624, replyNumber=0, likeNumber=82, createdTime=2022-07-13, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c4f1e2402624, moduleTitle=AACR 2022：第四代EGFR抑制剂BLU-945治疗晚期耐药的NSCLC早期结果公布, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c4f1e2402624)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852806, encodeId=7e0b18528068b, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=NLRP3抑制剂调节免疫微环境有助于改善肺动脉高压引起的急性右心衰竭, objectType=article, longId=220233, objectId=7213220233cc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7213220233cc, replyNumber=0, likeNumber=63, createdTime=2022-04-18, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7213220233cc, moduleTitle=NLRP3抑制剂调节免疫微环境有助于改善肺动脉高压引起的急性右心衰竭, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7213220233cc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852792, encodeId=6aa61852e924a, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Liver Cancer：免疫相关不良事件(irAEs)对晚期肝细胞癌患者使用免疫检查点抑制剂(ICIs)疗效的影响, objectType=article, longId=219336, objectId=97b7219336b4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=97b7219336b4, replyNumber=0, likeNumber=106, createdTime=2022-07-02, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=97b7219336b4, moduleTitle=Liver Cancer：免疫相关不良事件(irAEs)对晚期肝细胞癌患者使用免疫检查点抑制剂(ICIs)疗效的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=97b7219336b4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852996, encodeId=f6b91852996a6, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Stroke：症状性颈动脉狭窄患者血小板粘附抑制剂Revacept的疗效, objectType=article, longId=729284, objectId=02a9e29284cb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=02a9e29284cb, replyNumber=0, likeNumber=73, createdTime=2022-07-21, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=02a9e29284cb, moduleTitle=Stroke：症状性颈动脉狭窄患者血小板粘附抑制剂Revacept的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=02a9e29284cb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1853051, encodeId=a6fb1853051b6, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=【每日播报】-磺脲类药物联合DPP-4抑制剂的疗效, objectType=article, longId=738851, objectId=9b3ae388512b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9b3ae388512b, replyNumber=0, likeNumber=24, createdTime=2022-09-10, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9b3ae388512b, moduleTitle=【每日播报】-磺脲类药物联合DPP-4抑制剂的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9b3ae388512b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852940, encodeId=789a185294058, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=AACR 2022：TMB不能成为好的免疫检查点抑制剂的biomarker (RATIONALE 304研究)?, objectType=article, longId=724034, objectId=348fe24034fa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=348fe24034fa, replyNumber=0, likeNumber=80, createdTime=2023-02-19, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=348fe24034fa, moduleTitle=AACR 2022：TMB不能成为好的免疫检查点抑制剂的biomarker (RATIONALE 304研究)?, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=348fe24034fa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852923, encodeId=e2891852923df, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Front Oncol：低剂量白蛋白紫杉醇联合PD-1抑制剂（替雷利珠单抗）治疗老年晚期非小细胞肺癌（NSCLC）患者的疗效, objectType=article, longId=301507, objectId=2ec730150e2b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2ec730150e2b, replyNumber=0, likeNumber=76, createdTime=2022-10-25, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2ec730150e2b, moduleTitle=Front Oncol：低剂量白蛋白紫杉醇联合PD-1抑制剂（替雷利珠单抗）治疗老年晚期非小细胞肺癌（NSCLC）患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2ec730150e2b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852847, encodeId=d7dc185284ec4, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=GUT: 质子泵抑制剂有可能会导致结直肠癌风险的风险, objectType=article, longId=292241, objectId=3fb529224132, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3fb529224132, replyNumber=0, likeNumber=85, createdTime=2022-04-12, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3fb529224132, moduleTitle=GUT: 质子泵抑制剂有可能会导致结直肠癌风险的风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3fb529224132)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852973, encodeId=0f0318529e350, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=一表讲全！PD-1/PD-L1 免疫抑制剂使用宝典, objectType=article, longId=727591, objectId=61c0e27591d8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=61c0e27591d8, replyNumber=0, likeNumber=110, createdTime=2022-07-29, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=61c0e27591d8, moduleTitle=一表讲全！PD-1/PD-L1 免疫抑制剂使用宝典, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=61c0e27591d8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852833, encodeId=38aa18528337c, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Nature Aging：PDE5抑制剂再现传奇，或可防治阿尔茨海默病, objectType=article, longId=221672, objectId=555b2216e23a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=555b2216e23a, replyNumber=0, likeNumber=123, createdTime=2022-06-01, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=555b2216e23a, moduleTitle=Nature Aging：PDE5抑制剂再现传奇，或可防治阿尔茨海默病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=555b2216e23a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852823, encodeId=42f21852823ae, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=J Immunother Cancer：PD-L1抑制剂avelumab联合/不联合西妥昔单抗治疗既往治疗过的晚期肛管鳞状细胞癌(aSCAC)患者的疗效和安全性：CARACAS研究, objectType=article, longId=221205, objectId=3c79221205ea, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3c79221205ea, replyNumber=0, likeNumber=68, createdTime=2022-05-13, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3c79221205ea, moduleTitle=J Immunother Cancer：PD-L1抑制剂avelumab联合/不联合西妥昔单抗治疗既往治疗过的晚期肛管鳞状细胞癌(aSCAC)患者的疗效和安全性：CARACAS研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3c79221205ea)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852936, encodeId=12a218529366b, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=JAAD：新型氘化JAK抑制剂CTP-543治疗中重度斑秃的效果, objectType=article, longId=723835, objectId=b733e2383591, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b733e2383591, replyNumber=0, likeNumber=82, createdTime=2022-06-27, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b733e2383591, moduleTitle=JAAD：新型氘化JAK抑制剂CTP-543治疗中重度斑秃的效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b733e2383591)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852962, encodeId=799a18529623c, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=A&R：在未接种疫苗的人群中，细胞因子抑制剂治疗对SARS-CoV-2体液免疫反应的阳性率、血清转化率和持续时间的影响, objectType=article, longId=726444, objectId=581ae26444ca, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=581ae26444ca, replyNumber=0, likeNumber=68, createdTime=2022-07-03, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=581ae26444ca, moduleTitle=A&R：在未接种疫苗的人群中，细胞因子抑制剂治疗对SARS-CoV-2体液免疫反应的阳性率、血清转化率和持续时间的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=581ae26444ca)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

抑制剂

2020-05-29

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

JCEM：钠-葡萄糖协同转运蛋白2抑制剂对左心室功能的有益作用

2022-07-18

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Clin Cancer Res：mTOR抑制剂sapanisertib联合氟维司群治疗芳香化酶抑制剂进展后ER+/ HER2-的绝经后女性晚期乳腺癌患者的疗效

2022-11-30

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

J Allergy Clin Immunol：脱氧核糖核酸2抑制剂对银屑病的分子和临床作用

2022-10-22

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Front Oncol：回顾性分析实体恶性肿瘤伴有脑转移患者从免疫检查点抑制剂治疗的获益情况

2022-10-28

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

JAK抑制剂联合疗法FMX114治疗轻中度特应性皮炎，临床试验中招募了第一位患者

2022-08-30

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Rhizen Pharmaceuticals AG在AACR 2022公布其差异化的PARP和DHODH抑制剂项目的数据

2022-11-05

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

氯喹/羟氯喹：严重 COVID-19 中的炎症小体抑制剂？

2023-08-01

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

AACR 2022：第四代EGFR抑制剂BLU-945治疗晚期耐药的NSCLC早期结果公布

2022-07-13

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

NLRP3抑制剂调节免疫微环境有助于改善肺动脉高压引起的急性右心衰竭

2022-04-18

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Liver Cancer：免疫相关不良事件(irAEs)对晚期肝细胞癌患者使用免疫检查点抑制剂(ICIs)疗效的影响

2022-07-02

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Stroke：症状性颈动脉狭窄患者血小板粘附抑制剂Revacept的疗效

2022-07-21

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

【每日播报】-磺脲类药物联合DPP-4抑制剂的疗效

2022-09-10

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

AACR 2022：TMB不能成为好的免疫检查点抑制剂的biomarker (RATIONALE 304研究)?

2023-02-19

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Front Oncol：低剂量白蛋白紫杉醇联合PD-1抑制剂（替雷利珠单抗）治疗老年晚期非小细胞肺癌（NSCLC）患者的疗效

2022-10-25

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

GUT: 质子泵抑制剂有可能会导致结直肠癌风险的风险

2022-04-12

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

一表讲全！PD-1/PD-L1 免疫抑制剂使用宝典

2022-07-29

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Nature Aging：PDE5抑制剂再现传奇，或可防治阿尔茨海默病

2022-06-01

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

J Immunother Cancer：PD-L1抑制剂avelumab联合/不联合西妥昔单抗治疗既往治疗过的晚期肛管鳞状细胞癌(aSCAC)患者的疗效和安全性：CARACAS研究

2022-05-13

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

JAAD：新型氘化JAK抑制剂CTP-543治疗中重度斑秃的效果

2022-06-27

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

A&R：在未接种疫苗的人群中，细胞因子抑制剂治疗对SARS-CoV-2体液免疫反应的阳性率、血清转化率和持续时间的影响

2022-07-03

科室
- - 订阅+
  - 更多科室
工具
服务